The delayed approval and price setting of Novartis Pharma’s Zolgensma (onasemnogene abeparvovec), a gene therapy for spinal muscular atrophy (SMA) listed in May, has raised questions about how the sakigake designation system should be operated. Despite being designated for the…
ACADEMIA
Most Mild COVID-19 Patients Recovered on Avigan, but Careful Interpretations Needed for Single-Arm Study: Interim Report
Most mildly ill patients with COVID-19 recovered on the antiviral agent Avigan (favipiravir) in an observational clinical study in Japan, but the results should be interpreted carefully given that there is no control group set and many mild cases tend…
To read the full story
Related Article
ACADEMIA
- Nobel Laureate Honjo Sues Ono over Opdivo Royalties, Demands 22.6 Billion Yen
June 22, 2020
- NIID Aims to Start Preclinical Trials for Coronavirus Vaccines in Autumn: Flu Center Director
June 10, 2020
- Nobel Laureate Honjo Taking Ono to Court, Demands 22.6 Billion Yen
June 8, 2020
- Remdesivir Not Used as Severe Cases Decreased, Avigan/Alvesco Given to Several Dozen Patients: TMDU Hospital
June 5, 2020
- AnGes/Osaka Univ. Plan Small COVID-19 Vaccine Study from July, Larger One from September
June 5, 2020
When Jiho surveyed drug makers on the non-sales criteria they use to evaluate reps’ performance, it received a variety of…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Look into the heart of every successful company, the businesses that have made a real impact on the world, and you’ll notice they all share a common trait.The people. But not just any people, as Jim Collins famously said…“People are…